Fully remote versus hybrid supervision of pulmonary telerehabilitation in COVID-19: a randomized clinical trial

被引:0
作者
Vian, Bruna S. [1 ,2 ]
Ratti, Ligia S. [1 ]
Resende, Mariangela R. [3 ]
Conterno, Lucieni de O. [3 ]
Pereira, Monica C. [2 ]
机构
[1] Univ Estadual Campinas, Univ Hosp, Physiotherapy & Occupat Therapy Serv, Campinas, Brazil
[2] Univ Estadual Campinas, Fac Med Sci, Dept Internal Med, Div Pneumol, Campinas, Brazil
[3] Univ Estadual Campinas, Fac Med Sci, Dept Internal Med, Div Infectivol, Campinas, Brazil
基金
巴西圣保罗研究基金会;
关键词
Telerehabilitation; COVID-19; Walk test; Quality of life; 6-MINUTE WALK; STATEMENT; DISEASE; REHABILITATION; ADULTS; TESTS;
D O I
10.23736/S1973-9087.24.08634-9
中图分类号
R49 [康复医学];
学科分类号
100215 ;
摘要
BACKGROUND: The restrictions imposed by the COVID-19 pandemic have impeded the traditional rehabilitation process, prompting the widespread adoption of remote programs for the recovery of survivors. AIM: The aim of this study was to evaluate and compare the effectiveness of a pulmonary telerehabilitation program (PTRP) in the exclusively remote modality versus the hybrid modality (remote and face-to-face) in patients with persistent respiratory dysfunction following hospitalization for COVID-19 pneumonia, and to compare the functional capacity of patients who participated in a PTRP with those who did not. DESIGN: A randomised, interventional, prospective clinical trial was conducted. In parallel, an observational cohort study was conducted. SETTING: Outpatient rehabilitation clinic and home-based rehabilitation program. POPULATION: Thirty patients post-COVID-19 were randomised into two groups: G1 (fully remote supervision of PTRP) or G2 (hybrid supervision of PTRP). Thirty-seven post-COVID-19 patients were followed up without participating in PTRP (non-intervention group- NIG). METHODS: Patients with persistent respiratory dysfunction and reduced functional capacity, as measured by the Six Minute Walk Test (6MWT), after hospitalization for COVID-19 pneumonia, were considered eligible for a PTRP. To assess the efficacy of the PTRP, the primary outcome (I) was distance walked on the 6MWT (6MWD) and the secondary outcome (II) was quality of life as assessed by the SF-36 questionnaire. RESULTS: Both G1 and G2 demonstrated similar improvement in 6MWD, P<0.001 and quality of life (P<0.05). The IG showed higher 6MWD than the NIG (P<0.001). The increase in 6MWD for the IG was 140.5 m, while for the NIG it was 16.8 m (P=0.002). CONCLUSIONS: The PTRP was found to be a feasible and highly effective intervention for restoring functional capacity and improving quality of life, regardless of the type of supervision. Furthermore, this functional gain was maintained over the long term. In patients with pulmonary dysfunction, participation in the PTRP improved functional capacity compared with those who were simply advised to resume physical activity during recovery. CLINICAL REHABILITATION IMPACT: Telerehabilitation has been demonstrated to be a viable and efficacious alternative to traditional inperson programs in low-income contexts.
引用
收藏
页码:141 / 153
页数:13
相关论文
共 50 条
  • [41] Efficacy and Safety of Atazanavir/Ritonavir Versus Lopinavir/Ritonavir in Hospitalized COVID-19 Patients: A Randomized Clinical Trial
    Siami, Zeinab
    Dehghan, Danial
    Khavandegar, Armin
    Lak, Mehran
    Bakhtiyari, Mahmood
    IRANIAN RED CRESCENT MEDICAL JOURNAL, 2022, 24 (05)
  • [42] Investigating phenotypes of pulmonary COVID-19 recovery: A longitudinal observational prospective multicenter trial
    Sonnweber, Thomas
    Tymoszuk, Piotr
    Sahanic, Sabina
    Boehm, Anna
    Pizzini, Alex
    Luger, Anna
    Schwabl, Christoph
    Nairz, Manfred
    Grubwieser, Philipp
    Kurz, Katharina
    Koppelstaetter, Sabine
    Aichner, Magdalena
    Puchner, Bernhard
    Egger, Alexander
    Hoermann, Gregor
    Woell, Ewald
    Weiss, Guenter
    Widmann, Gerlig
    Tancevski, Ivan
    Loeffler-Ragg, Judith
    ELIFE, 2022, 11
  • [43] Methylene blue for COVID-19 ARDS: insights from a randomized Clinical Trial
    Sanei, Zahra Sadat
    Shahrahmani, Fatemeh
    Manesh, Behrooz Khaleghi
    Hamidi-alamdari, Daryoush
    Mehrad-Majd, Hassan
    Darban, Behzad Mavaji
    Mirdoosti, Seyedeh Motahareh
    Seddigh-Shamsi, Mohsen
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2025, 398 (02) : 1915 - 1924
  • [44] Safety and Efficacy of Incentive Spirometer in Covid-19 Pneumonia; a Randomized Clinical Trial
    Bargahi, Mohammad
    Alavi-Moghaddam, Mostafa
    Karimi, Mehdi
    Azizan, Zahra
    Jafarzadeh, Fateme
    Javaherian, Mohammad
    Soleimantabar, Hussein
    Mirbehbahani, Seyed Hamidreza
    ARCHIVES OF ACADEMIC EMERGENCY MEDICINE, 2024, 12 (01)
  • [45] Utilizing the sublingual form of squalene in COVID-19 patients: a randomized clinical trial
    Ebrahimi, Mahmoud
    Farhadian, Nafiseh
    Soflaei, Sara Saffar
    Amiri, Alireza
    Tanbakuchi, Davoud
    Oskooee, Rozita Khatamian
    Karimi, Mohammad
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [46] Telmisartan for treatment of Covid-19 patients: An open multicenter randomized clinical trial
    Duarte, Mariano
    Pelorosso, Facundo
    Nicolosi, Liliana N.
    Salgado, M. Victoria
    Vetulli, Hector
    Aquieri, Analia
    Azzato, Francisco
    Castro, Marcela
    Coyle, Javier
    Davolos, Ignacio
    Criado, Ignacio Fernandez
    Gregori, Rosana
    Mastrodonato, Pedro
    Rubio, Maria C.
    Sarquis, Sergio
    Wahlmann, Fernando
    Rothlin, Rodolfo P.
    ECLINICALMEDICINE, 2021, 37
  • [47] Efficacy of oral indomethacin in the treatment of COVID-19 infection; a randomized clinical trial
    Salmasi, Mehrzad
    Pourajam, Samaneh
    Ashrafi, Farzaneh
    Soltaninejad, Forogh
    Amra, Babak
    Ahmadikia, Zeinab
    Torki, Mehdi
    Darakhshandeh, Ali
    IMMUNOPATHOLOGIA PERSA, 2024, 10 (02):
  • [48] Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial
    Darazam, Ilad Alavi
    Shokouhi, Shervin
    Mardani, Masoud
    Pourhoseingholi, Mohamad Amin
    Rabiei, Mohammad Mahdi
    Hatami, Firouze
    Shabani, Minoosh
    Moradi, Omid
    Gharehbagh, Farid Javandoust
    Irvani, Seyed Sina Naghibi
    Amirdosara, Mahdi
    Hajiesmaeili, Mohammadreza
    Rezaei, Omidvar
    Khoshkar, Ali
    Lotfollahi, Legha
    Gachkar, Latif
    Dehbsneh, Hadiseh Shabanpour
    Khalili, Negar
    Soleymaninia, Azam
    Kusha, Akram Hoseyni
    Shoushtari, Maryam Taleb
    Torabinavid, Parham
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 99
  • [49] Utilizing the sublingual form of squalene in COVID-19 patients: a randomized clinical trial
    Mahmoud Ebrahimi
    Nafiseh Farhadian
    Sara Saffar Soflaei
    Alireza Amiri
    Davoud Tanbakuchi
    Rozita Khatamian Oskooee
    Mohammad Karimi
    Scientific Reports, 14
  • [50] Evaluation of anakinra in the management of patients with COVID-19 infection: A randomized clinical trial
    Elmekaty, Eman Zeyad I.
    Maklad, Aya
    Abouelhassan, Rawan
    Munir, Waqar
    Ibrahim, Mohamed Izham Mohamed
    Nair, Arun
    Alibrahim, Rim
    Iqbal, Fatima
    Al Bishawi, Ahmad
    Abdelmajid, Alaaeldin
    Aboukamar, Mohamed
    Hadi, Hamad Abdel
    Khattab, Mohammed Abu
    Al Soub, Hussam
    Al Maslamani, Muna
    FRONTIERS IN MICROBIOLOGY, 2023, 14